Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13238MR)

This product GTTS-WQ13238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13238MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6618MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ9569MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ2994MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ13492MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ5061MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ12314MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ10269MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ1960MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW